ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
ANI Pharma (ANIP) Misses Q4 EPS by 8c, Offers FY Guidance
February 23, 2016 8:03 AM ESTANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $0.52, $0.08 worse than the analyst estimate of $0.60. Revenue for the quarter came in at $18.04 million versus the consensus estimate of $18.13 million.
GUIDANCE:
ANI Pharma sees FY2016 revenue of $105-120 million, versus the... More



